Interestingly, other studies have described A2AR’s control of synaptic transmission and modulation of glutamate excitotoxicity and also the therapeutic potential of A2AR antagonists for many aging-related neurodegenerative pathologies [4], including temporal lobe epilepsy [53], Parkinson’s disease [54], Alzheimer’s disease [55, 56], and stress-induced long-term potentiation (LTP) deficits [57]. This evidence concerns the gene ADORA2A and early-onset autosomal dominant Alzheimer disease.